NCT04282018 2026-02-20Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabBeOne MedicinesPhase 1/2 Completed97 enrolled 43 charts
NCT03206970 2024-10-26Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)BeiGenePhase 2 Completed86 enrolled 16 charts 1 FDA